2/20/2026 | USA | economy | ✓ Verified - investing.com

Aveanna healthcare CFO Buckhalter sells $266k in AVAH stock

#Aveanna Healthcare #CFO Buckhalter #AVAH stock #Insider sales #Financial guidance #Healthcare sector #Market analysis #Investment firms

📌 Key Takeaways

Aveanna Healthcare CFO sold $266,097 worth of company stock to cover tax obligations
The sales involved 36,030 shares across three transactions from February 17-19, 2026
Despite the insider sales, Buckhalter still owns over 529,000 shares of the company
Aveanna recently raised its 2025 revenue and EBITDA guidance, with positive analyst response

📖 Full Retelling

Aveanna Healthcare Holdings Inc.'s (NASDAQ:AVAH) Chief Financial Officer Matthew Buckhalter sold a total of $266,097 worth of the company's stock in multiple transactions between February 17 and February 19, 2026, to cover tax obligations related to the vesting of equity awards. The sales involved 36,030 shares of common stock, with transactions occurring on each of the three days. On February 17, Buckhalter sold 9,351 shares at a weighted average price of $7.6451, with prices ranging from $7.47 to $7.97. The following day, he sold 13,167 shares at a weighted average price of $7.3829, with prices ranging from $7.175 to $7.53. The final sale occurred on February 19, with 13,512 shares sold at a weighted average price of $7.2082, with prices ranging from $7.06 to $7.29. Despite these insider sales, Buckhalter still directly owns 529,243 shares of Aveanna Healthcare Holdings Inc. The stock transactions came as AVAH shares have declined 6.4% over the past week and are down 9.2% year-to-date, though the stock has gained 54% over the past year. Despite the recent dip, analysts remain optimistic about the company's prospects. Aveanna Healthcare recently updated its financial projections, increasing its 2025 revenue guidance to a range of $2.425 billion to $2.445 billion, up from the previous outlook of more than $2.375 billion. The company also adjusted its 2025 EBITDA expectations to $318-322 million, up from over $300 million. Additionally, Aveanna has introduced its 2026 guidance, which surpassed consensus expectations during an industry event. Several investment firms have responded positively, with UBS and RBC Capital raising their price targets to $10 and $11 respectively, while Raymond James increased its target to $13. William Blair initiated coverage with an Outperform rating, acknowledging Aveanna's role in providing specialized home care services.

🏷️ Themes

Insider Trading, Healthcare Sector, Financial Performance, Market Analysis

Entity Intersection Graph

No entity connections available yet for this article.

Deep Analysis

Why It Matters

The CFO’s sale of 36,030 shares for $266,097 was to cover tax obligations, not a sign of distress, but it highlights the company’s stock volatility and the importance of insider activity for investors. The company’s upgraded 2025 revenue and EBITDA guidance, along with analyst price target hikes, suggest a potentially stronger financial outlook.

Context & Background

CFO Matthew Buckhalter sold 36,030 shares to cover tax obligations related to equity awards
AVAH stock has fallen 6.4% in the past week and 9.2% year‑to‑date, but has gained 54% over the past year
The company raised its 2025 revenue guidance to $2.425‑$2.445 billion and EBITDA to $318‑$322 million
Analysts UBS, RBC Capital, and Raymond James increased their price targets to $10, $11, and $13 respectively

What Happens Next

Investors will likely monitor the company’s upcoming quarterly results to assess whether the upgraded guidance translates into earnings growth. The stock may rebound if the market views the guidance and analyst upgrades positively, while the CFO may continue to hold a significant shareholding.

Frequently Asked Questions

Why did the CFO sell shares?

The sale was to cover tax obligations related to the vesting of equity awards.

Does the insider sale affect the company’s operations?

No, the sale does not impact the company’s day‑to‑day operations or financial health.

What new revenue and EBITDA guidance has the company issued?

The company now expects 2025 revenue of $2.425 to $2.445 billion and EBITDA of $318 to $322 million.

What are the current analyst price targets for AVAH?

UBS has a target of $10, RBC Capital $11, and Raymond James $13.

}

Original Source

              try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Nvidia and OpenAI close to finalizing smaller, $30 bln investment- FT U.S. stocks end lower after hawkish Fed minutes; Walmart guidance falls short Gold largely flat as investors weigh geopolitical tensions, hawkish Fed minutes Berenberg sees more than 50% upside in this small-cap software stock (South Africa Philippines Nigeria) Aveanna healthcare CFO Buckhalter sells $266k in AVAH stock By Investing.com Insider Trading Published 02/19/2026, 09:43 PM Aveanna healthcare CFO Buckhalter sells $266k in AVAH stock 0 AVAH 0.27% Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) Chief Financial Officer Matthew Buckhalter sold a total of 36,030 shares of common stock in multiple transactions between February 17 and February 19, 2026. The sales amounted to $266,097. On February 17, Buckhalter sold 9,351 shares at a weighted average price of $7.6451, with prices ranging from $7.47 to $7.97. On February 18, he sold 13,167 shares at a weighted average price of $7.3829, with prices ranging from $7.175 to $7.53. The final sale occurred on February 19, with 13,512 shares sold at a weighted average price of $7.2082, with prices ranging from $7.06 to $7.29. These transactions were executed to cover tax obligations related to the vesting of equity awards. Following these transactions, Buckhalter directly owns 529,243 shares of Aveanna Healthcare Holdings Inc.The sales came as AVAH stock has declined 6.4% over the past week and is down 9.2% year-to-date, though the stock has gained 54% over the past year. According to InvestingPro analysis, the stock appears undervalued at current levels, with additional insights available for subscribers. In other recent news, Aveanna Healthcare Holdings Inc. has updated its financial projections, increasing its 2025 revenue guidance to a range of $2.425 billion to $2.445 billion, a rise from its previous outlook of more than $2.375 billion. The company also adjusted its 2025 EBITDA expectations ...
            

Read full article at source

Source

investing.com